VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
GL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
GLGlobe Life Inc.
$179.25$13.9B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksGLFinancials

Globe Life Inc. (GL) Financials

30Y historyFree accessUpdated daily

Underwriting profitability remains resilient with a combined ratio of 76.4% in 2026Q1, though revenue growth has slowed to 3.82% year-over-year, suggesting potential saturation in core markets.

GL Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Revenue6.08B6B5.78B5.45B5.23B5.12B4.74B4.53B4.31B4.16B3.93B3.77B3.62B3.49B3.59B3.38B3.37B3.12B3.2B3.49B3.42B3.13B3.07B2.93B2.76B2.71B2.52B2.23B2.16B2.07B2.21B
Revenue Growth %4.03%3.82%6.07%4.22%2.06%8.08%4.66%4.93%3.82%5.63%4.48%4.02%3.61%-2.65%6.28%0.29%8.11%-2.54%-8.33%1.92%9.45%1.77%4.79%6.16%2%7.47%13.11%3.2%4.19%-6.11%6.69%
Medical Costs & Claims3.76B3.99B3.91B3.81B3.69B3.43B3.45B3.21B3.07B257.25M2.85B2.7B2.54B2.45B2.54B2.37B2.37B2.17B2.18B2.29B2.24B2.01B1.99B1.91B1.69B1.76B1.61B2.72B2.53B1.25B1.28B
Medical Cost Ratio %61.93%66.6%67.63%69.89%70.51%67.06%72.9%70.85%71.2%6.19%72.37%71.68%70.21%70.03%70.9%70.29%70.24%69.64%68.23%65.78%65.5%64.34%64.88%65.23%61.3%64.88%64.09%122.18%117.32%60.36%57.89%
Gross Profit2.31B2B1.87B1.64B1.54B1.69B1.28B1.32B1.24B3.9B1.09B1.07B1.08B1.05B1.04B1B1B945.76M1.02B1.19B1.18B1.11B1.08B1.02B1.07B950.61M904.48M-493.95M-373.72M820.9M928.9M
Gross Margin %38.07%33.4%32.37%30.11%29.49%32.94%27.1%29.15%28.8%93.81%27.63%28.32%29.79%29.97%29.1%29.71%29.76%30.36%31.77%34.22%34.5%35.66%35.12%34.77%38.7%35.12%35.91%-22.18%-17.32%39.64%42.11%
Gross Profit Growth %-7.14%14.02%6.43%-8.65%31.38%-2.71%6.19%-68.12%258.64%1.91%-1.1%3%0.24%4.12%0.1%5.99%-6.85%-14.91%1.11%5.87%3.35%5.83%-4.63%12.42%5.1%283.11%-32.17%-145.53%-11.63%8.76%
Operating Expenses799.13M540.97M543.62M445.98M439.04M412.39M387.34M388.49M379.16M3.24B314.86M300.5M293.92M291.9M278.69M279.54M251.8M368.68M386.91M396.45M406.59M383.24M357.82M366.1M478.59M349.18M338.62M-896.36M-820.72M55.2M433.77M
OpEx / Revenue %13.15%9.02%9.41%8.19%8.4%8.05%8.17%8.58%8.79%77.96%8%7.98%8.12%8.35%7.76%8.28%7.48%11.84%12.11%11.37%11.88%12.26%11.65%12.49%17.33%12.9%13.44%-40.25%-38.03%2.67%19.66%
Depreciation & Amortization0000000000000000000391.01M377.49M349.96M347.25M4.81M302.73M5.82M6.86M8.84M7.93M8M9.06M
Combined Ratio %75.08%75.62%77.04%78.08%78.91%75.11%81.08%79.43%79.98%84.15%80.37%79.66%78.33%78.38%78.66%78.57%77.71%81.47%80.34%77.15%77.39%76.6%76.53%77.72%78.63%77.78%77.53%81.93%79.29%63.03%77.55%
Operating Income1.51B1.46B1.33B1.19B1.1B1.27B896.68M931.28M863.67M923.93M772.24M766.19M784.68M755.32M765.99M723.78M750.57M577.08M628.4M796.8M773.57M731.52M720.8M653.1M590.05M601.43M565.86M402.41M446.99M765.7M495.13M
Operating Margin %24.92%24.38%22.96%21.92%21.09%24.89%18.92%20.57%20.02%22.23%19.63%20.34%21.67%21.62%21.34%21.43%22.29%18.53%19.66%22.85%22.61%23.4%23.47%22.28%21.37%22.22%22.47%18.07%20.71%36.97%22.45%
Operating Income Growth %-10.26%11.08%8.36%-13.53%42.15%-3.71%7.83%-6.52%19.64%0.79%-2.36%3.89%-1.39%5.83%-3.57%30.06%-8.17%-21.14%3%5.75%1.49%10.37%10.69%-1.89%6.29%40.62%-9.97%-41.62%54.65%15.64%
EBITDA1.61B1.59B1.45B1.3B1.19B1.36B983.39M1.02B953.75M915.18M855.58M842.83M860.8M835.78M846.5M801.69M826.1M647.01M691.63M1.19B1.15B1.08B1.07B657.91M892.78M607.25M572.72M411.25M454.93M773.7M504.19M
EBITDA Margin %26.47%26.54%25.16%23.8%22.82%26.52%20.75%22.43%22.1%22.02%21.74%22.38%23.78%23.92%23.58%23.74%24.53%20.77%21.64%34.07%33.65%34.6%34.77%22.45%32.33%22.43%22.74%18.47%21.08%37.36%22.86%
Interest Expense140.23M141.22M127.09M102.32M90.39M83.49M86.7M84.31M90.08M85M83.34M76.64M76.13M80.46M80.51M77.91M75.53M69.93M63.23M67.56M73.14M60.93M56.49M56.1M28.59M44.51M54.49M52.34M56.33M71.9M73.61M
Non-Operating Income-94.03M-129.02M-127.09M-102.32M-90.39M-83.49M-86.7M-84.31M-90.08M8.75M-83.34M-76.64M-76.13M-80.46M-80.51M-77.91M-75.53M-69.93M-63.23M-67.56M-73.14M-60.93M-56.49M-56.1M-28.59M-44.51M-51.58M-52.34M-56.33M693.8M-73.61M
Pretax Income1.46B1.44B1.33B1.19B1.1B1.27B896.68M931.28M863.67M830.65M772.24M766.19M784.68M755.32M765.99M723.78M750.57M577.08M628.4M796.8M773.57M731.52M720.8M653.1M590.05M601.43M562.96M402.41M446.99M408.7M495.13M
Pretax Margin %23.99%24%22.96%21.92%21.09%24.89%18.92%20.57%20.02%19.99%19.63%20.34%21.67%21.62%21.34%21.43%22.29%18.53%19.66%22.85%22.61%23.4%23.47%22.28%21.37%22.22%22.35%18.07%20.71%19.73%22.45%
Income Tax280.66M278.57M255.88M223.51M207.72M243.5M164.91M170.4M162.16M-627.62M232.65M249.89M256.6M248.11M236.67M226.17M246.47M191.02M198.7M269.27M254.94M236.13M245.08M223M197.04M205.97M190.84M134.32M154.34M138.4M180.62M
Effective Tax Rate %19.25%19.35%19.29%18.72%18.85%19.1%18.39%18.3%18.78%-75.56%30.13%32.62%32.7%32.85%30.9%31.25%32.84%33.1%31.62%33.79%32.96%32.28%34%34.14%33.39%34.25%33.9%33.38%34.53%33.86%36.48%
Net Income1.18B1.16B1.07B970.75M894.39M1.03B731.77M760.79M701.47M1.45B549.78M527.1M542.94M528.47M529.32M497.16M498.87M404.95M452.26M527.53M518.63M495.39M468.56M430.1M387.28M356.51M362M273.96M244.44M347.6M311.37M
Net Margin %19.37%19.36%18.53%17.82%17.11%20.13%15.44%16.8%16.26%34.99%13.97%14%15%15.12%14.75%14.72%14.81%13%14.15%15.13%15.16%15.85%15.25%14.67%14.03%13.17%14.37%12.3%11.33%16.78%14.12%
Net Income Growth %9.9%8.44%10.3%8.54%-13.26%40.91%-3.81%8.46%-51.76%164.47%4.3%-2.92%2.74%-0.16%6.47%-0.34%23.19%-10.46%-14.27%1.72%4.69%5.73%8.94%11.06%8.63%-1.52%32.14%12.07%-29.68%11.63%117.39%
EPS (Diluted)14.7514.0611.9410.079.047.226.826.836.0812.224.494.164.093.793.603.142.802.172.272.452.282.081.861.661.411.271.250.940.801.080.97
EPS Growth %17.98%17.76%18.57%11.39%25.21%5.87%-0.15%12.34%-50.25%172.16%7.93%1.71%7.92%5.28%14.65%12.14%29.03%-4.41%-7.35%7.46%9.62%11.83%12.05%17.73%11.02%1.6%32.98%17.5%-25.93%11.34%120.45%
EPS (Basic)-14.3011.9910.219.137.306.906.976.2212.504.584.214.153.843.653.192.832.172.282.492.312.101.891.671.421.281.260.950.811.080.97
Diluted Shares Outstanding79.8M80.85M84.75M96.36M98.98M103.17M107.22M111.38M115.25M118.98M122.37M126.76M132.64M139.56M146.85M164.72M184.69M186.83M199.16M215.65M227.47M238.17M251.61M259.44M271.3M279.84M288.83M292.06M305.2M312.69M322.16M

Key Metrics

Growth RegimeStable
ProfitabilityStrong
Balance SheetHealthy
Cash FlowRobust
Top Statement Risk

Captive agency distribution volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Premium Growth Facing Saturation Headwinds

As reported in recent financial filings, Globe Life's revenue growth has moderated to 3.82% year-over-year, suggesting that the company's reliance on its captive agency model may be encountering market saturation within its core blue-collar demographic segments, warranting closer scrutiny of future new business production.

The deceleration in top-line expansion indicates that the company's historical reliance on human-mediated sales may be reaching a point of diminishing returns. Investors should monitor whether the current growth trajectory reflects a structural ceiling in the affinity-group model or merely a temporary lull in agent recruitment efficiency.

Underwriting Profitability Remains Highly Resilient

Based on the provided quarterly data, Globe Life maintains a strong underwriting profile with a combined ratio consistently below 80%, peaking at 78.8% in 2025Q2, which underscores the company's ability to price risk effectively despite periodic volatility in claims and benefits expenses.

The consistent sub-80% combined ratio suggests that the company's niche focus on middle-income life and supplemental health products provides a significant buffer against broader industry underwriting pressures. This performance implies that the firm's actuarial assumptions remain well-calibrated, though the sensitivity to mortality spikes remains a latent risk factor.

Earnings Quality Subject to Actuarial Assumptions

According to the company's income statement data, the net income volatility observed in 2025Q3, where earnings reached $387.8 million, suggests that reported profitability may be heavily influenced by subjective actuarial adjustments rather than purely organic underwriting gains, necessitating a cautious interpretation of core earnings power.

The significant quarterly fluctuations in net income, despite relatively stable premium revenue, imply that reserve releases or changes in deferred acquisition cost amortization may be masking underlying operational trends. Analysts should investigate the extent to which these non-cash accounting adjustments contribute to the reported bottom line to avoid overestimating the sustainability of recent earnings spikes.

Operational Efficiency Through Niche Distribution

As indicated by the company's financial statements, the disciplined management of administrative overhead relative to premium volume suggests that Globe Life leverages its captive agency structure to maintain a competitive expense ratio, effectively insulating its margins from the high acquisition costs typically seen in broader insurance markets.

The company's ability to sustain high operating margins appears to be a direct result of its specialized distribution network, which minimizes the need for expensive, broad-market advertising. This operational efficiency serves as a critical moat, though it remains vulnerable to any regulatory shifts that might force a restructuring of the commission-based incentive models currently driving agent productivity.

GL — Frequently Asked Questions

Quick answers to the most common questions about buying GL stock.

What was Globe Life Inc.'s (GL) revenue in 2025?

For fiscal year 2025, Globe Life Inc. (GL) reported total revenue of $6.00B. This represents a 171.9% increase compared to $2.21B in 1996.

Is Globe Life Inc. (GL) profitable?

Globe Life Inc. (GL) is profitable, generating $1.16B in net income for the fiscal year ending 2025 with a net profit margin of 19.4%.

What is Globe Life Inc.'s operating profit margin?

Globe Life Inc. (GL) reported an operating income of $1.46B, resulting in an operating profit margin of 24.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Globe Life Inc.'s gross profit and gross margin?

Globe Life Inc. (GL) generated $2.00B in gross profit for the year, representing a gross profit margin of 33.4%. This demonstrates the company's core pricing power and production efficiency.